Reproducibility of the bronchoconstrictive response to eucapnic voluntary hyperpnoea by Williams, NC et al.
1 
 
Title: Reproducibility of the bronchoconstrictive response to eucapnic voluntary hyperpnoea  
 
 
Authors: Williams NC, Johnson MA, Hunter KA, Sharpe GR 
Affiliation: Sport, Health and Performance Enhancement (SHAPE) Research Group, School 
of Science and Technology, Nottingham Trent University, Nottingham, NG11 8NS, UK 
Email: Neil.williams@ntu.ac.uk; Michael.johnson@ntu.ac.uk; Kirsty.hunter@ntu.ac.uk; 
Graham.sharpe@ntu.ac.uk 
 
 
Corresponding Author 
Dr Michael A Johnson  
School of Science and Technology  
Nottingham Trent University 
Nottingham  
NG11 8NS 
UK 
Telephone:+44 (0)115 8483362 
Fax: +44 (0)115 8486680 
E-mail: Michael.johnson@ntu.ac.uk 
 
 
 
Abbreviations: EVH, eucapnic voluntary hyperpnoea; HIB, hyperpnoea-induced 
bronchoconstriction; EIB, exercise-induced bronchoconstriction; FVC, forced vital capacity; 
FEV1, forced expiratory volume in 1 s; MVV, maximal voluntary ventilation;  ̇ , minute 
ventilation; AUC, area under the curve; CV, coefficient of variation; SMC, smallest 
meaningful change.  
2 
 
Abstract 
Background: Eucapnic voluntary hyperpnoea (EVH) is considered an effective 
bronchoprovocation challenge for identifying exercise-induced bronchoconstriction (EIB). 
However, the reproducibility of the hyperpnoea-induced bronchoconstriction (HIB) response 
elicited by EVH remains unknown and was therefore the focus of this study.  
Methods: Two cohorts of 16 physically active males (each cohort comprised 8 controls and 8 
with physician diagnosis of asthma) participated in two studies of the short- and long-term 
reproducibility of the bronchoconstrictive response to an EVH test with dry air. EVH was 
performed on days 0, 7, 14, and 21 (short-term study), and 0, 35, and 70 (long-term study). 
HIB was diagnosed by a ≥10% fall in forced expiratory volume in 1 s (F  1) after EVH. 
Results: On day 0 of the short-term study, FEV1 fell by 2  1% (P < 0.05) and 27  18% (P < 
0.01) from pre- to post-EVH in control and HIB-positive groups respectively. The post-EVH 
fall in FEV1 did not differ across the short-term study test days. In the HIB-positive group, the 
day-to-day coefficient of variation, reproducibility, and smallest meaningful change for the 
fall in FEV1 were 12%, 328 mL, and 164 mL, respectively. On day 0 of the long-term study, 
FEV1 fell by 2  2% and 25  18% (P < 0.01) after EVH in control and HIB-positive groups 
respectively. The post-EVH fall in FEV1 did not differ across the long-term study test days. In 
the HIB-positive group, the day-to-day coefficient of variation, reproducibility, and smallest 
meaningful change for the fall in FEV1 were 10%, 196 mL, and 98 mL respectively. 
Conclusion: The EVH test elicits a reproducible bronchoconstrictive response in physically 
active males with physician diagnosed asthma. These data thus support the clinical utility of 
the EVH test for EIB screening and monitoring.  
Key words: Exercise-induced bronchoconstriction; asthma; eucapnic voluntary hyperpnoea; 
reproducibility.  
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Introduction 
Asthma affects 5-10% of the population in developed countries
1
 and is the most 
common chronic medical condition reported among Olympic athletes with a prevalence of 
around 8%.
2
 At least 80% of individuals with clinically diagnosed asthma
3
 and up to 50% of 
particular elite athlete populations
4
 will also experience exercise-induced bronchoconstriction 
(EIB). EIB is characterised by transient airway narrowing during or after exercise and is 
ascribed to airway drying and subsequent changes in airway osmolality, which results in 
degranulation of inflammatory cells and release of inflammatory mediators.
5,6
  
Diagnosis of EIB should not be based exclusively on self-reported symptoms
7-9
 as 
they lack sensitivity and specificity.
10-14
  Instead, EIB diagnosis should be objective and based 
on a fall in forced expiratory volume in 1 s (FEV1) after an exercise challenge, or a surrogate 
for exercise such as eucapnic voluntary hyperpnoea (EVH).
7,9
 Exercise challenges are highly 
specific, but they lack sensitivity and thus the rate of false-negative diagnoses can be high.
13,15
 
Exercise challenges are also difficult to standardise due to changing environmental conditions 
and ventilatory responses, which determine the degree of EIB.
15,16
  The EVH test comprises 6 
min of voluntary hyperpnoea using a dry gas and high minute ventilation ( ̇ ). Hyperpnoea-
induced bronchoconstriction (HIB) is diagnosed when FEV1 falls by ≥10%.
17,18
  The EVH test 
can be tightly controlled, has high specificity and sensitivity for diagnosing EIB, and results 
in fewer false-negative diagnoses compared with exercise challenges.
15,19-21
 It is therefore 
considered a superior bronchoprovocation challenge for identifying EIB.
15,22
   
The clinical utility of the EVH test critically depends on the extent to which it elicits a 
reproducible day-to-day fall in FEV1. Reproducibility is determined by the measurement error 
and within-individual fluctuation, which may increase with longer time intervals.
23
 However, 
few studies have examined the reproducibility of HIB elicited by EVH across different time 
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intervals and using robust methods. Some studies failed to use appropriate statistical 
techniques to evaluate reproducibility,
17
 whereas others examined elite swimmers
14
 who may 
have a unique EIB pathophysiology.
24,25
 Price et al.
26
 reported poor reproducibility for the fall 
in FEV1 (95% limits of agreement: -10.7% to 9.5%) after EVH in 32 individuals (6 with 
physician diagnosed asthma) with borderline HIB (10% fall in FEV1). The reproducibility of 
HIB elicited by EVH in individuals with physician diagnosed asthma and more severe HIB is 
therefore unknown.  
Thus, the aim of the present study was to evaluate the short- (21 days) and long- (70 
days) term test-retest reproducibility of HIB elicited by EVH in individuals with physician 
diagnosed asthma who were also positive for HIB during initial screening.  
Methods 
Following approval from the Nottingham Trent University Human Ethics Committee, 
two cohorts of 16 physically active (completing 4-6 hours of aerobic exercise per week) males 
provided written informed consent to participate in a short-term (4 EVH tests each separated 
by 7 days) or long-term (3 EVH tests each separated by 35 days) study of HIB 
reproducibility. All participants were non-smokers and had no history of smoking. Each 
cohort comprised 8 control participants and 8 HIB-positive participants. Inclusion criteria for 
HIB-positive participants included physician diagnosis of asthma, a baseline FEV1 >65% of 
predicted,
17
 and a ≥10% fall in FEV1 following EVH.
9
 On commencing the short-term study, 
HIB-positive participants were taking the following prescribed medication: N = 5, short 
acting β2 agonists; N = 1, combination of short acting β2 agonists and inhaled corticosteroids; 
N = 1, combination of short and long acting β2 agonists and inhaled corticosteroids; N = 1, 
combination of short acting β2 agonists, inhaled corticosteroids, and leukotriene modifiers. 
On commencing the long-term study, HIB-positive participants were taking the following 
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prescribed medication: N = 5, short acting β2 agonists; N = 1 short acting β2 agonists and 
inhaled corticosteroids; N = 2, short and long acting β2 agonists and inhaled corticosteroids. 
Inclusion criteria for the HIB-positive group did not consider changes of medication prior to 
starting the study, but exclusion criteria included a change in medication during the study. 
Throughout the study, participants adhered to their usual habitual exercise regime and avoided 
strenuous exercise during the 48 h prior to testing.
18
   
Pulmonary function and EVH test 
Baseline pulmonary function (forced vital capacity (FVC) and FEV1) was assessed 
according to published guidelines
27
 using a pneumotachograph (Pneumotrac, Vitalograph, 
Buckinghm, UK) as previously described.
28,29
   
For the 2 weeks prior to each EVH test, participants were free from any chest or upper 
respiratory tract infection.
19
 On EVH test days participants abstained from caffeine and 
alcohol as they can influence asthma exacerbations,
30,31
 and arrived at the laboratory at least 2 
h post-prandial. For each participant, EVH tests were performed at the same time of day. 
Participants with asthma ceased their medication prior to each EVH test (inhaled 
corticosteroids and leukotriene modifiers: 4 days; inhaled long acting β2 agonists: 2 days; 
anti-histamines: 2 days; inhaled short acting β2 agonists: the day of the test).18,19  
The EVH test comprised 6 min of voluntary hyperpnoea at a target  ̇  of 85% of the 
predicted maximal voluntary ventilation (MVV) (30 x baseline FEV1).
17,18
 Participants 
breathed through a flanged mouthpiece (Series 9060; Hans Rudolph, Missouri, USA) 
connected to a flow sensor (ZAN variable orifice pneumotach; Nspire Health, Oberthulba, 
Germany) that was calibrated using a 3 L syringe. Gas concentrations were measured using 
fast responding laser diode absorption spectroscopy sensors, which were calibrated using 
gases of known concentration (5% CO2, 15% O2, balance N2; BOC, Guilford, UK), and 
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ventilatory and pulmonary gas exchange variables were measured breath-by-breath (ZAN 
600USB; Nspire Health) as previously described.
28,29
 A two-way non-rebreathing valve (2700 
Series; Hans Rudolph) was connected distally to the flow sensor and the inspiratory port was 
connected via a 1.2 m length of corrugated tubing (internal diameter: 35 mm) to a 150 L 
capacity Douglas bag. Participants inspired from the Douglas bag which was continuously 
filled with gases of known concentration (21% O2, 5% CO2, balance N2; BOC).
32
 The 
inspired gas was at room temperature (19-21°C) and of low humidity (<3%). During EVH, 
participants faced a computer monitor and received real-time visual feedback of  ̇ , and end-
tidal CO2 was continuously monitored to ensure that isocapnia was maintained. After EVH, 
pulmonary function was assessed in duplicate at 3, 6 and 16 min, and the highest values 
recorded were used for subsequent analysis. After the EVH test, HIB-positive participants 
were supervised in the laboratory until their FEV1 was within 10% of their baseline FEV1. 
Statistical analysis 
The short- and long-term reproducibility studies were analysed separately using the 
Statistical Package for the Social Sciences (SPSS, Chicago, IL). Between-group comparisons 
(HIB-positive vs. control) for baseline FVC and FEV1 were made using independent samples 
t-tests. One-way repeated measures ANOVA followed by Bonferroni adjusted pairwise 
comparisons was used to evaluate the within-group effects of day (short-term study: day 0, 7, 
14, and 21; long-term study: day 0, 35, and 70) on baseline FVC and FEV1. One-way repeated 
measures ANOVA followed by Bonferroni adjusted pairwise comparisons was used to 
evaluate the within-group effects of time after EVH (3, 6, and 16 min) on FVC and FEV1. On 
all occasions there were no differences between these time points for FVC and FEV1 and, 
therefore, the three values were averaged and used for further analyses, including 
reproducibility statistics. One-way repeated measures ANOVA followed by Bonferroni 
adjusted pairwise comparisons was used to evaluate the within-group effects of day on the 
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average FVC and FEV1 measured after EVH. In HIB-positive participants the area under the 
curve for %∆F  1 during the 16 min period after EVH (AUC0-16%∆F  1) was calculated 
using the trapezoidal rule. 
Day-to-day variation in baseline FVC and FEV1, and the fall in FEV1 after EVH, was 
calculated as the within-participant coefficient of variation (CV). Measurement error and 
reproducibility were calculated for FVC and FEV1 measured before and after EVH. The same 
statistics were also calculated for the absolute change in FVC and FEV1 from baseline to post-
EVH. The smallest meaningful change was subsequently determined.
33,34
 Statistical 
significance was set at P < 0.05. Results are presented as mean  SD, unless otherwise 
indicated. 
Results 
No participants were excluded during the course of the study. Participant 
characteristics and baseline (mean across study days) pulmonary function before EVH are 
shown in Table 1. In both short- and long-term studies FVC before EVH did not differ 
between HIB-positive and control groups. In the short-term study there was a trend for 
baseline FEV1 to be lower in the HIB-positive group compared with the control group (P = 
0.056). In the long-term study baseline FEV1 was lower in the HIB-positive group compared 
with the control group (P < 0.05). The mean target  ̇  during EVH was therefore lower in the 
HIB-positive group compared with the control group in both short-term (121  25 vs. 141  
12 Lmin-1, P = 0.056) and long-term (113  25 vs. 139  11 Lmin-1, P < 0.05) studies. In 
both studies and in both groups FVC and FEV1 measured before EVH, and therefore the 
target  ̇  during EVH, were not different between test days. The achieved  ̇  during EVH 
was not different between test days in both short-term (HIB-positive: 121  21 Lmin-1, range 
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72-156 Lmin-1, 86  11% MVV; control: 139  12 Lmin-1, range 118-156 Lmin-1, 84  2% 
MVV) and long-term (HIB-positive: 114  23 Lmin-1, range 71-154 Lmin-1, 88  9% MVV; 
control: 139  12 Lmin-1, range 118-146 Lmin-1, 82  4% MVV) studies. End-tidal CO2 
during EVH (39.5  1.7 mmHg) was not different from rest (38.7  1.8 mmHg) with a mean 
difference of 0.8  1.4 mmHg (range: -3.5-3.5 mmHg) (data pooled from both groups and 
both studies).  
Short term study 
Control group 
On day 0 of the short-term study, FVC was unchanged after EVH in the control group. 
Conversely, FEV1 fell 3  2% 3 min after EVH (P < 0.05) and remained below baseline 
throughout the post-EVH period (P < 0.05). The fall in FEV1 after EVH was not different 
between the 4 short-term study days (Table 2). 
HIB-positive group 
On day 0 of the short-term study, FVC fell 11  14% 3 min after EVH in the HIB-
positive group (P < 0.05) and remained below baseline throughout the post-EVH period (P < 
0.05). The fall in FVC after EVH was not different between the 4 short-term study days 
(Table 2). On day 0 of the short-term study, FEV1 fell 27  18% 3 min after EVH (P < 0.01) 
and remained below baseline throughout the post-EVH period (6 min: P < 0.01; 16 min: P < 
0.05). The fall in FEV1 after EVH was not different between the 4 short-term study days 
(Table 2). All HIB-positive participants experienced a >10% fall in FEV1 after every EVH 
test and the consistency of the fall between days is shown in Figure 1. The AUC0-16%∆F  1 
on day 0 of the short-term study was 390  263. The AUC0-16%∆F  1 was not different 
between the 4 short-term study days. Between-day reproducibility in pulmonary function for 
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the short-term study is shown in Table 3. In the HIB-positive group, the smallest meaningful 
change for the fall in FEV1 after EVH represented 17% of the absolute fall.  
Long term study 
Control group 
On day 0 of the long-term study, FVC was unchanged after EVH in the control group, 
whereas FEV1 fell 3  1% 6 min after EVH (P < 0.01). FEV1 at 3 and 16 min after EVH was 
not different from baseline. The fall in FEV1 was not different between the 3 long-term study 
days (Table 4).  
HIB-positive group 
On day 0 of the long-term study, FVC fell 20  15% 6 min after EVH in the HIB-
positive group (P < 0.05). There was also a trend for FVC to be lower than baseline 3 (P = 
0.07) and 16 min (P = 0.09) after EVH. The fall in FVC after EVH was not different between 
the 3 long-term study days (Table 4). On day 0 of the long-term study, FEV1 fell 27  19% 3 
min after EVH (P < 0.05) and remained below baseline throughout the post-EVH period (6 
min: P < 0.01; 16 min: P < 0.05). The fall in FEV1 was not different between the 3 long-term 
study days (Table 4). All HIB-positive participants experienced a >10% fall in FEV1 after 
every EVH test and the consistency of the fall between days is shown in Figure 2. The AUC0-
16%∆F  1 on day 0 of the long-term study was 364  256. The AUC0-16%∆F  1 was not 
different between the 3 long-term study days. Between-day reproducibility in pulmonary 
function for the long-term study is shown in Table 5. In the HIB-positive group, the smallest 
meaningful change for the fall in FEV1 after EVH represented 11% of the absolute fall.  
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Discussion 
The present study is the first to report the reproducibility of the bronchoconstrictive 
response elicited by the 6 min EVH test in recreationally active males with physician 
diagnosed asthma. The main finding was that the EVH test elicits a reproducible fall in FEV1 
when evaluated over short- (21 days) and long-term (70 days) periods. These data therefore 
support the clinical utility of the EVH test for EIB screening and monitoring.  
The EVH test is an indirect bronchoprovocation test that is considered a suitable 
objective surrogate for identifying EIB.
9,35
 The test can be tightly controlled and standardised, 
results in fewer false-negative EIB diagnoses compared with exercise challenges, and can 
diagnose EIB in previously undiagnosed and asymptomatic individuals.
15,19-21
 The clinical 
utility of the EVH test is, in part, dependent on the extent to which it elicits a reproducible fall 
in FEV1. Two previous studies reported good reproducibility for the fall in FEV1 after two 
EVH tests performed on separate occasions; however, one failed to use appropriate statistical 
techniques to evaluate reproducibility,
17
 and the other studied competitive swimmers
14
 who 
may have a unique EIB pathophysiology.
24,25
 The degree of HIB can be classified as mild (10-
19.9% fall in FEV1), moderate (20-29.9% fall in FEV1), or severe (≥30% fall in F  1),
18
 and 
Price et al.
26
 have raised concerns regarding the reproducibility of HIB in individuals 
demonstrating a mild or borderline (10%) post-EVH fall in FEV1, which may result in 
misdiagnosis of EIB. Conversely, in the present study the post-EVH fall in FEV1 was highly 
reproducible for all HIB-positive participants, including those with mild HIB (Figures 1 and 
2). Although the reasons for this inter-study discrepancy remain unclear, only 6 of 32 
participants studied by Price et al.
26
 had physician diagnosed asthma and the post-EVH fall in 
FEV1 (10  8%) was much smaller than in the present study (27%). Our data show that in 
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recreationally active males with physician diagnosed asthma the degree of HIB elicited by 
EVH is reproducible for up to 70 days irrespective of HIB severity.  
Based on patient perception of change, the minimal important difference for 
improvement or worsening in FEV1 is 10% from baseline.
36
  The post-EVH fall in FEV1 in 
the control groups is thus unlikely to have clinical significance. In the HIB-positive groups 
the mean FEV1 at baseline was 4.03 and 3.75 L in the short- and long-term studies 
respectively, and thus an improvement or worsening in FEV1 of 403 and 375 mL respectively 
would be perceptible. The smallest meaningful change for the post-EVH fall in FEV1 in the 
short- (164 mL) and long-term (98 mL) studies therefore demonstrates that the EVH test is 
sufficiently sensitive to detect clinically relevant changes in HIB that might occur with, for 
example, a therapeutic intervention.  
 It is essential that isocapnia is maintained during EVH because hyperpnoea-induced 
hypocapnia can cause bronchoconstriction in individuals with asthma, whereas hypercapnia 
can cause bronchodilation in individuals with and without asthma.
37
  The gold standard EVH 
gas mixture (4.5-5% CO2) is based on the work of Phillips et al.
32
 who showed that isocapnia 
is maintained over a range of  ̇  from 40-105 Lmin
-1
. Although in the present study the 
achieved  ̇  during EVH exceeded this range, end-tidal CO2 scarcely deviated from rest and, 
therefore, the observed HIB was not influenced by hypocapnia or hypercapnia. The present 
study therefore extends the findings of Phillips et al.
32
 by showing that an EVH gas mixture 
containing 5% CO2 can maintain isocapnia over a range of  ̇  from 71-156 Lmin
-1
.  
Limitations  
Caution is warranted when generalising the present findings to women. Changes in 
sex hormones during the menstrual cycle have been linked with cyclic changes in lung 
function in women with and without asthma,
38
 and around half of women with asthma 
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experience an aggravation of asthma symptoms and increased medication use during the 
premenstrual or menstrual phase.
39,40
  Women are also 2.38 times less likely than males to 
achieve a  ̇  of 60% MVV during EVH (a criterion for an adequate test), although they may 
also experience bronchoconstriction at a lower  ̇  than men.
41
 These confounders may 
influence the ability of the EVH test to elicit a reproducible fall in FEV1 in women with 
asthma. Further studies are therefore needed to establish the utility of the EVH test in women 
with asthma, including whether a reproducible bronchoconstrictive response is elicited across 
different time intervals and phases of the menstrual cycle.  
 The EVH test is very provocative and may not represent the ventilatory and 
environmental challenges associated with most forms of exercise.
19
 However, exercise 
challenges are difficult to standardise and they lack sensitivity, which can result in false-
negative diagnoses. Thus, a positive HIB diagnosis from the EVH test identifies that an 
individual is at risk of EIB and should therefore explore appropriate pharmacological 
treatment. 
Conclusions 
In conclusion, the degree of HIB elicited by the EVH test is reproducible over short- 
(21 days) and long-term (70 days) periods in recreationally active males with physician 
diagnosed asthma. These data support the clinical utility of the EVH test for EIB screening 
and monitoring, and for evaluating the effectiveness of therapeutic interventions for reducing 
EIB.  
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Table 1. Participant characteristics and baseline pulmonary function (pooled data across all 
test days) for short- and long-term studies. Values are mean  SD. *Significant difference 
between groups in the long-term study (P < 0.05).  
 Short-term study Long-term study 
 HIB-positive Control HIB-positive Control 
Age (yr) 28  7 25  3 31  9 26  4 
Height (cm) 177  6 181  6 175  2 181  5 
Body mass (kg) 76  10 79  8 73  10 78  9 
FVC (L) 5.14  0.93 5.56  0.44 4.66  0.68 5.25  0.40 
   % predicted 100  12 102  7 94  10 97  6 
FEV1 (L) 4.03  0.84 4.71  0.41 3.75  0.84* 4.63  0.37 
   % predicted  93  15 103  6 91  14 102  5 
HIB, hyperpnoea-induced bronchoconstriction; FVC, forced vital capacity; FEV1, forced 
expiratory volume in 1 s. 
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Table 2 Relative and absolute changes in pulmonary function after eucapnic voluntary 
hyperpnoea (EVH) performed on 4 separate days in the short-term study. Values represent the 
mean ± SD of the three post-EVH measurements.  
Day 0 7 14 21 
Change % mL % mL % mL % mL 
EIB-positive 
ΔFVC -11  13 -511  540 -16  18 -735  785 -14  15 -663  662 -14  14 -612  557 
ΔFEV1 -27  18 -973  514 -27  20 -1000  616 -27  19 -962  558 -26  19 -939  607 
Control 
ΔFVC -1   1 -52  67 -1   1 -54  39 -2   2 -88  91 -0   1 -10  49 
ΔFEV1 -2   1 -105  64 -2   2 -105  91 -2   2 -115  86 -2   2 -106  79 
FVC, forced vital capacity; FEV1, forced expiratory volume in 1 s. 
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Table 3 Between-day reproducibility in baseline pulmonary function and the fall in 
pulmonary function after eucapnic voluntary hyperpnoea performed on 4 separate days (day 
0, 7, 14, and 21) in the short-term study.  
 Day-to-day CV (%) Measurement error Reproducibility SMC 
HIB-positive     
    Baseline FVC (mL) 3 182 503 252 
    Baseline FEV1 (mL) 2 95 263 131 
    Fall in FEV1 (mL) 12 118 328 164 
Control     
    Baseline FVC (mL) 1 77 215 107 
    Baseline FEV1 (mL) 2 100 277 139 
CV, coefficient of variation; SMC, smallest meaningful change; HIB, hyperpnoea-induced bronchoconstriction; 
FVC, forced vital capacity; FEV1, forced expiratory volume in 1 s. 
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Table 4 Relative and absolute changes in pulmonary function after eucapnic voluntary 
hyperpnoea (EVH) in the long-term study. Values represent the mean ± SD of the three post-
EVH measurements.  
Day 0 35 70 
Change % mL % mL % mL 
EIB-positive 
ΔFVC -17  14 -747  584 -16  11 -697  437 -16  14 -701  563 
ΔFEV1 -25  18 -893  524 -25  16 -888  441 -25  16 -833  446 
Control 
ΔFVC -1   2 -57  87 -2   2 -89  87 -1   2 -39  114 
ΔFEV1 -2   2 -101  84 -2   2 -72  64 -3   2 -115  71 
FVC, forced vital capacity; FEV1, forced expiratory volume in 1. 
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Table 5 Between-day reproducibility in baseline pulmonary function and the fall in 
pulmonary function after eucapnic voluntary hyperpnoea performed on 3 separate days (day 
0, 35, and 70) in the long-term study.  
 Day-to-day CV (%) Measurement error Reproducibility SMC 
HIB-positive     
    Baseline FVC (mL) 3 141 392 196 
    Baseline FEV1 (mL) 2 89 248 124 
    Fall in FEV1 (mL) 10 71 196 98 
Control     
    Baseline FVC (mL) 2 114 316 158 
    Baseline FEV1 (mL) 2 84 232 116 
CV, coefficient of variation; SMC, smallest meaningful change; FVC, forced vital capacity; FEV1, forced 
expiratory volume in 1 s.
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Figure 1. Individual falls in forced expiratory volume in 1 s (FEV1) after eucapnic voluntary 
hyperpnoea (EVH) in the short-term study. Data are for HIB-positive participants only, with 
identical symbols representing the same HIB-positive participant.  
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Figure 2. Individual falls in forced expiratory volume in 1 s (FEV1) after eucapnic voluntary 
hyperpnoea (EVH) in the long-term study. Data are for HIB-positive participants only, with 
identical symbols representing the same HIB-positive participant.  
 
 
 
